Baidu
map

JCO:李强教授发现基于PRO的主动管理模式能减轻肺癌患者出院后症状负担和并发症

2022-01-15 网络 网络

四川省肿瘤医院李强教授、石丘玲教授团队传来中国最强音!该团队牵头的一项多中心随机对照临床研究(CN-PRO-Lung 2研究)成果,在全球顶尖肿瘤学期刊《Journal of Clinical Onc

2022年1月8日,四川省肿瘤医院李强教授、石丘玲教授团队传来中国最强音!该团队牵头的一项多中心随机对照临床研究(CN-PRO-Lung 2研究)成果,在全球顶尖肿瘤学期刊《Journal of Clinical Oncology》上发表。

图片

 

全文链接https://ascopubs.org/doi/abs/10.1200/JCO.21.01344

该研究旨在评估肺癌术后早期,基于患者报告结局(Patient-Reported Outcome, PRO)的症状管理的有效性和可行性。结果显示,基于患者报告结局(PRO)的症状管理模式,可减轻肺癌患者出院后4周内的症状负担和减少并发症。

将手术前,临床诊断为肺癌的患者被1:1随机分配到接受术后基于PRO的症状管理(干预组)或常规护理(对照组)。所有患者在术前、术后每天以及出院后每周两次直到第4周,通过电子PRO系统报告MD安德森症状量表-肺癌子表(MDASI-LC)上的自我症状。在干预组中,预设的5个目标症状(疼痛、乏力、睡眠不安、气短、咳嗽)中的一个超过预警值(≥4分),系统将实时生成警报并发送给医生进行处理。对照组患者仅接受上述PRO症状监测,而无预警和医生主动处理过程。

主要研究结局为患者出院时的症状阈值事件(任何目标症状评分≥4分)的数量,采用PP分析。

研究共纳入患者166例,干预组和对照组各83例。结果显示:出院时,干预组报告的症状阈值事件比对照组少(M[IQR],0[0-2]vs.2[0-3]; P=0.007);在出院后4周,干预组和对照组之间保持了这一差异,(M[IQR],0[0-0]vs.0[0-1];P=0.018)。干预组的并发症发生率明显低于对照组(21.5% vs.40.6%;P=0.019)。医生处理每次预警的中位时间为3分钟。

据悉,该研究为研究者发起的临床研究,由四川省肿瘤医院胸外科中心PRO研究团队负责组织实施。从团队组建、研究设计、项目立项、平台构建、研究实施到成果发表,共历时长达5年之久。

该研究在全球首次验证了基于PRO的主动症状监测-预警-反馈全程管理模式可加速肺癌患者术后康复,且患者满意度高;首次在中国文化背景和医疗体系下,证明了基于PRO的主动管理模式在外科领域有效且有较好的可行性,有利于向临床推广

研究形成了PRO用于肺癌术后管理的高级别循证医学证据,将为改变患者住院期间“被动式”管理、出院后“散养”状态和解决“看病难”等问题提供新思路,并有望填补国内基于PRO的围手术期全程管理空白。

该成果的发表将促进患者报告结局(PRO)这一新型临床指标在我国恶性肿瘤临床科研及临床实践中的应用,也将奠定四川省肿瘤医院在国内外PRO临床应用研究领域的领先地位。下一步,研究团队将基于《“健康中国2030”规划纲要》,聚焦恶性肿瘤等患者的症状管理模式,开发更多智能化关键技术,在多种疾病和多个地区进行示范推广。

作者简历

图片

 

 

图片

 

 

供稿:四川省肿瘤医院

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891689, encodeId=c5e01891689bf, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Feb 11 19:35:02 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990781, encodeId=25461990e81ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 10 19:35:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758409, encodeId=feba1e5840923, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 07 22:35:02 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602416, encodeId=ae991602416b4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625334, encodeId=c46c16253347f, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-02-11 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891689, encodeId=c5e01891689bf, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Feb 11 19:35:02 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990781, encodeId=25461990e81ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 10 19:35:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758409, encodeId=feba1e5840923, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 07 22:35:02 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602416, encodeId=ae991602416b4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625334, encodeId=c46c16253347f, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1891689, encodeId=c5e01891689bf, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Feb 11 19:35:02 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990781, encodeId=25461990e81ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 10 19:35:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758409, encodeId=feba1e5840923, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 07 22:35:02 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602416, encodeId=ae991602416b4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625334, encodeId=c46c16253347f, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-06-07 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1891689, encodeId=c5e01891689bf, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Feb 11 19:35:02 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990781, encodeId=25461990e81ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 10 19:35:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758409, encodeId=feba1e5840923, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 07 22:35:02 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602416, encodeId=ae991602416b4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625334, encodeId=c46c16253347f, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-17 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1891689, encodeId=c5e01891689bf, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Feb 11 19:35:02 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990781, encodeId=25461990e81ec, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Apr 10 19:35:02 CST 2022, time=2022-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758409, encodeId=feba1e5840923, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jun 07 22:35:02 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602416, encodeId=ae991602416b4, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625334, encodeId=c46c16253347f, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Mon Jan 17 00:35:02 CST 2022, time=2022-01-17, status=1, ipAttribution=)]

相关资讯

肺癌,靶向及免疫治疗药物汇总表(2022年1月)

肺癌,靶向及免疫治疗药物汇总表(2022年1月)

张力教授:2021年肺癌免疫治疗年终盘点

方文峰,张力(中山大学肿瘤防治中心 内科,广州 510060)

今日探报:诺华长效降脂siRNA疗法获FDA批准上市;研究表明,利用一滴血或许就能快速检测出早期肺癌……

未知君拥有五条自研的First-in-class微生态药物管线,与北京大学肿瘤亿元、北京协和医院、南方医科大学南方医院等国内众多著名医院展开临床方面的合作,多款临床药物均展现出显著疗效。

PNAS:利用一滴血或许就能快速检测出人类的早期肺癌

本文研究结果表明,从患者诊断前所测定的代谢组学预测模型的值或许能帮助预测局部患病患者的5年生存率。

探索头条:The Lancet:五种癌症一发现就是晚期 早筛早诊绝非空话!

饮食方式、生活习惯和周围环境中的许多因素,都可能会增加患癌风险。

第三届全国肺癌个体化精准治疗新近进展研讨会顺利召开,为肺癌诊疗开创崭新的局面

本次大会,国内外肿瘤学著名专家及基础研究领域知名学者共同携手,围绕肺癌精准诊治最新进展及面临的挑战展开深入的讨论。

Baidu
map
Baidu
map
Baidu
map